CompletedPhase 1NCT04935801

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against Dengue Virus

Studying Dengue fever

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Gylden Pharma Ltd
Principal Investigator: Blaise Genton, Prof
Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland
Intervention: LD vehicle-GNP(biological)
Enrollment: 26 enrolled
Eligibility: 18-45 years · All sexes
Timeline: 2021 – 2022

Study locations (1)

Center for Primary Care and Public Health, (Unisante), Lausanne, Canton of Vaud, Switzerland

Collaborators

Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland · University of Lausanne Hospitals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04935801 on ClinicalTrials.gov

Other trials for Dengue fever

Additional recruiting or active studies for the same condition.

See all trials for Dengue fever →

← Back to all trials